Study: FDG-PET/CT appears to help detect additional thyroid tumors

07/9/2013 | HealthImaging.com

In a study published in the Journal of Nuclear Medicine, FDG-PET/CT appeared to be effective in detecting differentiated thyroid carcinoma lesions that traditional protocols failed to identify. Researchers evaluated 18F-FDG-PET/CT findings in patients simultaneously receiving I-131 therapy and found additional tumors in up to 46% of the patients. "F-18 FDG PET/CT is useful for the detection of recurrent DTC lesions, especially in patients with iodine-negative tumors and elevated serum thyroglobulin levels," according to researchers.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA